[2]
Chou HK, Tsao YT, Lin SH. An unusual cause of thyrotoxic periodic paralysis: triiodothyronine-containing weight reducing agents. The American journal of the medical sciences. 2009 Jan:337(1):71-3. doi: 10.1097/01.MAJ.0000310783.66897.b6. Epub
[PubMed PMID: 19002009]
[3]
Lin SH, Lin YF, Chen DT, Chu P, Hsu CW, Halperin ML. Laboratory tests to determine the cause of hypokalemia and paralysis. Archives of internal medicine. 2004 Jul 26:164(14):1561-6
[PubMed PMID: 15277290]
[4]
Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine. 1992 May:71(3):109-20
[PubMed PMID: 1635436]
Level 3 (low-level) evidence
[5]
Liu Z, Braverman LE, Malabanan A. Thyrotoxic periodic paralysis in a Hispanic man after the administration of prednisone. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2006 Jul-Aug:12(4):427-31
[PubMed PMID: 16901800]
[6]
McFadzean AJ, Yeung R. Periodic paralysis complicating thyrotoxicosis in Chinese. British medical journal. 1967 Feb 25:1(5538):451-5
[PubMed PMID: 6017520]
[7]
Hsieh MJ, Lyu RK, Chang WN, Chang KH, Chen CM, Chang HS, Wu YR, Chen ST, Ro LS. Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. European journal of neurology. 2008 Jun:15(6):559-64. doi: 10.1111/j.1468-1331.2008.02132.x. Epub 2008 Apr 10
[PubMed PMID: 18410374]
[8]
Forrest L, Platts J. Ecstasy-induced thyrotoxic periodic paralysis. BMJ case reports. 2009:2009():. pii: bcr09.2009.2280. doi: 10.1136/bcr.09.2009.2280. Epub 2009 Dec 22
[PubMed PMID: 22190983]
Level 3 (low-level) evidence
[9]
OKINAKA S, SHIZUME K, IINO S, WATANABE A, IRIE M, NOGUCHI A, KUMA S, KUMA K, ITO T. The association of periodic paralysis and hyperthyroidism in Japan. The Journal of clinical endocrinology and metabolism. 1957 Dec:17(12):1454-9
[PubMed PMID: 13481091]
[10]
Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. The Journal of clinical endocrinology and metabolism. 2006 Jul:91(7):2490-5
[PubMed PMID: 16608889]
[11]
Shizume K, Shishiba Y, Kuma K, Noguchi S, Tajiri J, Ito K, Noh JY. Comparison of the incidence of association of periodic paralysis and hyperthyroidism in Japan in 1957 and 1991. Endocrinologia japonica. 1992 Jun:39(3):315-8
[PubMed PMID: 1425456]
[12]
Cesur M, Bayram F, Temel MA, Ozkaya M, Kocer A, Ertorer ME, Koc F, Kaya A, Gullu S. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series. Clinical endocrinology. 2008 Jan:68(1):143-52
[PubMed PMID: 17897330]
Level 2 (mid-level) evidence
[13]
Bazzani M, Benati L, Bosi M, Iorini M, Panizza M. Hypokalemic thyrotoxic paralysis: a rare cause of tetraparesis with acute onset in Europeans. Italian journal of neurological sciences. 1998 Oct:19(5):307-9
[PubMed PMID: 10933451]
[14]
Satam N, More V, Shanbag P, Kalgutkar A. Fatal thyrotoxic periodic paralysis with normokalemia. Indian journal of pediatrics. 2007 Nov:74(11):1041-3
[PubMed PMID: 18057690]
[15]
El-Hennawy AS, Nesa M, Mahmood AK. Thyrotoxic hypokalemic periodic paralysis triggered by high carbohydrate diet. American journal of therapeutics. 2007 Sep-Oct:14(5):499-501
[PubMed PMID: 17890941]
[17]
Mohapatra BN, Lenka SK, Acharya M, Majhi C, Oram G, Tudu KM. Clinical and Aetiological Spectrum of Hypokalemic Flaccid Paralysis in Western Odisha. The Journal of the Association of Physicians of India. 2016 May:64(5):52-58
[PubMed PMID: 27735149]
[18]
Verma V, Kumar Y, Kotwal N, Upreti V, Hari Kumar KVS, Singh Y, Menon AS. Thyrotoxic periodic paralysis: A retrospective, observational study from India. The Indian journal of medical research. 2020 Jan:151(1):42-46. doi: 10.4103/ijmr.IJMR_335_18. Epub
[PubMed PMID: 32134013]
Level 2 (mid-level) evidence
[19]
Sthaneshwar P, Prathibha R, Yap SF. Thyrotoxic periodic paralysis: a report of 3 Malaysian cases and a review of its pathology. The Malaysian journal of pathology. 2005 Jun:27(1):29-32
[PubMed PMID: 16676690]
Level 3 (low-level) evidence
[20]
Aldasouqi S, Bokhari SA, Khan PM, Al-Zahrani AS. Thyrotoxic periodic paralysis in a Saudi patient complicated by life-threatening arrhythmia. Saudi medical journal. 2009 Apr:30(4):564-8
[PubMed PMID: 19370290]
Level 2 (mid-level) evidence
[21]
Patel H, Wilches LV, Guerrero J. Thyrotoxic periodic paralysis: diversity in America. The Journal of emergency medicine. 2014 Jun:46(6):760-2. doi: 10.1016/j.jemermed.2013.08.104. Epub 2013 Dec 5
[PubMed PMID: 24315723]
[22]
Elston MS, Orr-Walker BJ, Dissanayake AM, Conaglen JV. Thyrotoxic, hypokalaemic periodic paralysis: Polynesians, an ethnic group at risk. Internal medicine journal. 2007 May:37(5):303-7
[PubMed PMID: 17504277]
[23]
Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundamental & clinical pharmacology. 2010 Oct:24(5):595-605. doi: 10.1111/j.1472-8206.2010.00859.x. Epub
[PubMed PMID: 20618871]
[24]
Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ (Clinical research ed.). 1991 Nov 2:303(6810):1096-9
[PubMed PMID: 1660744]
[25]
Chaudhury S, Ismail-Beigi F, Gick GG, Levenson R, Edelman IS. Effect of thyroid hormone on the abundance of Na,K-adenosine triphosphatase alpha-subunit messenger ribonucleic acid. Molecular endocrinology (Baltimore, Md.). 1987 Jan:1(1):83-9
[PubMed PMID: 2842662]
[26]
Ginsberg AM, Clutter WE, Shah SD, Cryer PE. Triiodothyronine-induced thyrotoxicosis increases mononuclear leukocyte beta-adrenergic receptor density in man. The Journal of clinical investigation. 1981 Jun:67(6):1785-91
[PubMed PMID: 6263953]
[27]
Lee KO, Taylor EA, Oh VM, Cheah JS, Aw SE. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. Lancet (London, England). 1991 May 4:337(8749):1063-4
[PubMed PMID: 1673496]
[28]
Soonthornpun S, Setasuban W, Thamprasit A. Insulin resistance in subjects with a history of thyrotoxic periodic paralysis (TPP). Clinical endocrinology. 2009 May:70(5):794-7. doi: 10.1111/j.1365-2265.2008.03395.x. Epub 2008 Aug 28
[PubMed PMID: 18759868]
[29]
Guerra M, Rodriguez del Castillo A, Battaner E, Mas M. Androgens stimulate preoptic area Na+,K+-ATPase activity in male rats. Neuroscience letters. 1987 Jul 9:78(1):97-100
[PubMed PMID: 3039424]
Level 3 (low-level) evidence
[30]
Cheng CJ, Lin SH, Lo YF, Yang SS, Hsu YJ, Cannon SC, Huang CL. Identification and functional characterization of Kir2.6 mutations associated with non-familial hypokalemic periodic paralysis. The Journal of biological chemistry. 2011 Aug 5:286(31):27425-35. doi: 10.1074/jbc.M111.249656. Epub 2011 Jun 10
[PubMed PMID: 21665951]
[31]
Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, Jongjaroenprasert W, Liang MC, Khoo DH, Cheah JS, Ho SC, Bernstein HS, Maciel RM, Brown RH Jr, Ptácek LJ. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010 Jan 8:140(1):88-98. doi: 10.1016/j.cell.2009.12.024. Epub
[PubMed PMID: 20074522]
[32]
Ruff RL. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current. Neurology. 1999 Oct 22:53(7):1556-63
[PubMed PMID: 10534267]
[33]
Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, Meola G, Schorge S, Kullmann DM, Davis MB, Hanna MG. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. 2009 May 5:72(18):1544-7. doi: 10.1212/01.wnl.0000342387.65477.46. Epub 2008 Dec 31
[PubMed PMID: 19118277]
Level 3 (low-level) evidence
[34]
Puwanant A, Ruff RL. INa and IKir are reduced in Type 1 hypokalemic and thyrotoxic periodic paralysis. Muscle & nerve. 2010 Sep:42(3):315-27. doi: 10.1002/mus.21693. Epub
[PubMed PMID: 20589886]
[35]
Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Archives of internal medicine. 1999 Mar 22:159(6):601-6
[PubMed PMID: 10090117]
[36]
Pompeo A, Nepa A, Maddestra M, Feliziani V, Genovesi N. Thyrotoxic hypokalemic periodic paralysis: An overlooked pathology in western countries. European journal of internal medicine. 2007 Sep:18(5):380-90
[PubMed PMID: 17693226]
[37]
Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: clinical challenges. Journal of thyroid research. 2014:2014():649502. doi: 10.1155/2014/649502. Epub 2014 Feb 20
[PubMed PMID: 24695373]
[38]
Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, Tristani-Firouzi M, Tawil R, Griggs RC, CINCH investigators. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain : a journal of neurology. 2006 Jan:129(Pt 1):8-17
[PubMed PMID: 16195244]
[39]
Lopez S, Henderson SO. Electrocardiogram changes in Thyrotoxic Periodic Paralysis. The western journal of emergency medicine. 2012 Dec:13(6):512-3. doi: 10.5811/westjem.2011.11.12127. Epub
[PubMed PMID: 23359336]
[40]
Puvanendran K, Cheah JS, Wong PK. Electromyographic (EMG) study in thyrotoxic periodic paralysis. Australian and New Zealand journal of medicine. 1977 Oct:7(5):507-10
[PubMed PMID: 272170]
[41]
Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2001 Mar:37(3):620-3
[PubMed PMID: 11228188]
[42]
Yu TS, Tseng CF, Chuang YY, Yeung LK, Lu KC. Potassium chloride supplementation alone may not improve hypokalemia in thyrotoxic hypokalemic periodic paralysis. The Journal of emergency medicine. 2007 Apr:32(3):263-5
[PubMed PMID: 17394988]
[43]
Tessier JJ, Neu SK, Horning KK. Thyrotoxic periodic paralysis (TPP) in a 28-year-old sudanese man started on prednisone. Journal of the American Board of Family Medicine : JABFM. 2010 Jul-Aug:23(4):551-4. doi: 10.3122/jabfm.2010.04.090220. Epub
[PubMed PMID: 20616298]